
    
      Ascending dose design includes 3 dose levels. Tolerance data up to at least 14 days post
      dosing from at least 6 subjects of the previous cohort will be reviewed before proceeding
      with a next dose. Total duration of the study per subject is approximately 15 weeks
      (including screening period).
    
  